CLINICAL EVIDENCE — PROCEDURAL OUTCOMES TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)

OUTSTANDING PROCEDURAL PERFORMANCE

The latest study results demonstrate excellent procedural performance.

EVOLUT PRO STUDY1

The Evolut PRO Study is a prospective, multicenter, non-randomized, single-arm study. Primary safety endpoints were all-cause mortality and disabling stroke at 30 days, and the primary efficacy endpoint was percentage of patients with no or trace aortic regurgitation at 30 days.

  • Study Status/Duration: 1-year outcomes reported/
    5-year follow-up
  • Sample Size: N = 60
  • Devices: Evolut PRO TAV

Pro PVL Data

SURTAVI CONTINUED ACCESS STUDY2

Patients underwent attempted TAV implant under the same inclusion and exclusion criteria and trial procedures as the SURTAVI Trial, with no randomization to surgery.

  • Study Status/Duration: 30-day outcomes reported/5-year follow-up
  • Sample Size: N = 275
  • Devices: Evolut R 93%/CoreValve 7%, TAV

Surtavi CAS 30 days

See the Medtronic TAVI Clinical Evidence Compendium for additional study results.

CONTATTI

Medtronic Italia

+39 02 241371
Via Varesina 162
20156 Milano Italia

CONTACT

US

For any information

CLICK HERE

MEDTRONIC

ACADEMY

View more clinical data and access procedural resources.

LOG IN OR REGISTER
1

Williams, as presented in poster at ACC.18

2

Van Mieghem N, et al. Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial. Presented at TCT 2017.